Abstracts tagged "autoantigens"

Abstract Number: 2291 • 2018 ACR/ARHP Annual Meeting
Longitudinal Course of the Disease in Anti-Mi2 Patients: More Intense Muscle Weakness, Good Response to Treatment and Progressive Reduction of Autoantibody Titers
Iago Pinal-Fernandez^1,2, Katherine Pak³, Maria Casal-Dominguez^4,5, Wilson Huang⁴, Jemima Albayda⁶, Eleni Tiniakou⁷, Julie J. Paik¹, Christopher A. Mecoli⁸, Sonye K. Danoff⁹, Lisa Christopher-Stine⁹ and Andrew Mammen^3,10, ¹Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²Muscle Diseases Unit, National Institute of Arthritis and Musculoskeletal and Skin Diseases. National Institutes of Health, Bethesda, MD, ³National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ⁴NIAMS, NIH, Bethesda, MD, ⁵Johns Hopkins Medical School, Baltimore, MD, ⁶Johns Hopkins University School of Medicine, Baltimore, MD, ⁷Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁸Internal Medicine/Rheumatology, Johns Hopkins University, Baltimore, MD, ⁹Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, ¹⁰Center Tower Ste 5300, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Autoantibodies targeting the Mi-2 (Mi-2a and Mi-2b) nuclear antigen in patients with dermatomyositis (DM) were first described in 1985. However, little is known about…
Abstract Number: 4 • 2018 ACR/ARHP Annual Meeting
Anti-Jo1 Positive Myositis Patients Display a Characteristic IgG Fc-Glycan Profile Which Is Further Enhanced in Anti-Jo1 Autoantibodies
Catia Fernandes-Cerqueira^1,2, Nuria Renard^1,2, Antonella Notarnicola^1,2, Edvard Wigren^1,2,3, Susanne Graslund^1,2,3, Roman Zubarev⁴, Ingrid E. Lundberg^1,2 and Susanna L. Lundström⁴, ¹Department of Medicine, Division of Rheumatology, Karolinska Institutet, Stockholm, Sweden, ²Center for Molecular Medicine, Stockholm, Sweden, ³Structural Genomics Consortium, Stockholm, Sweden, ⁴Department of Medical Biochemistry and Biophysics, Division of Physiological Chemistry I, Stockholm, Sweden
Background/Purpose: IgG Fc-glycans affect IgG function and are altered in autoimmune diseases and autoantibodies. Anti-histidyl tRNA synthetase autoantibodies (anti-Jo1) are frequent in myositis associated with…
Abstract Number: 16 • 2018 ACR/ARHP Annual Meeting
Comprehensive Antibody Profiling Using High Density Peptide Arrays Reveals Novel Citrullinated Protein Targets in Rheumatoid Arthritis Serum Samples
Ken Lo¹, Hanying Li², Eric Sullivan² and Jigar Patel², ¹Technology Innovation, Roche Sequencing Solutions - Madison, Madison, WI, ²Roche Sequencing Solutions - Madison, Madison, WI
Background/Purpose: Autoantibodies against citrullinated proteins are found in 64-89% of rheumatoid arthritis (RA) patients, with a specificity of 88-99%. While citrullinated vimentin, fibrin and histone…
Abstract Number: 2010 • 2018 ACR/ARHP Annual Meeting
Anti-Endothelial Cell Antibodies in Pediatric Rheumatic Diseases
Rie Karasawa¹, Toshiko Sato¹, Megumi Tanaka¹, Mayumi Tamaki¹, Kazuo Yudoh¹ and James Jarvis², ¹Institute of Medical Science, St. Marianna University School of Medicine, Kawasaki, Japan, ²Pediatrics, University at Buffalo Jacobs School of Medicine & Biomedical Sciences, Buffalo, NY
Background/Purpose: Anti-endothelial cell antibodies (AECA) are antibodies detected in multiple autoimmune and inflammatory diseases. Increased levels of such antibodies may be involved in disease activity…
Abstract Number: 2056 • 2018 ACR/ARHP Annual Meeting
Citrullination Is Not a Determinant in the Lack of Tolerance to Peptidylarginine Deiminase 2 and 4 in Rheumatoid Arthritis
Pooja Naik¹, Ryan Davis², Jon T. Giles³, Felipe Andrade⁴ and Erika Darrah⁵, ¹Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ³Columbia University, New York, NY, ⁴Medicine/Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁵Department of Medicine/Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Peptidylarginine deiminase (PAD) 2 and 4 are targets of the humoral response in RA. However, the mechanisms by which these enzymes become immunogenic in…
Abstract Number: 26 • 2017 ACR/ARHP Annual Meeting
Single B Cell Analysis Revealed the Relationship Among the Cytokine Profile, Antibody Affinity, and Pathogenic Roles of Autoantigen-Reactive B Cells in Systemic Sclerosis
Takemichi Fukasawa¹, Ayumi Yoshizaki², Satoshi Ebata¹, Kouki Nakamura¹, Ryosuke Saigusa¹, Takashi Yamashita¹, Yoshihide Asano³, Yutaka Kazoe⁴, Kazuma Mawatari⁴, Takehiko Kitamori⁴ and Shinichi Sato⁵, ¹Dermatology, University of Tokyo, Graduate School of Medicine, Tokyo, Japan, ²Department of Dermatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, ³Applied Chemistry, University of Tokyo, Graduate School of Medicine, Tokyo, Japan, ⁴Applied Chemistry, University of Tokyo, Graduate School of Engineering, Tokyo, Japan, ⁵Department of Dermatology, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Japan
Background/Purpose: Recent studies have indicated that B cells play critical roles in systemic autoimmunity and disease expression through various functions such as induction of the…
Abstract Number: 39 • 2017 ACR/ARHP Annual Meeting
Protein Array Technology Identifies Rituximab-Treated Non-Responder Rheumatoid Arthritis Patients to Generate New Autoantibody Repertoires during Treatment
Zoltán Konthur¹, Melvin Michael Wiemkes², Thomas Häupl², Gerd R. Burmester² and Karl Skriner², ¹Department of Biomolecular Systems, Max Planck Institute of Colloids and Interfaces, Potsdam, Germany, ²Department of Rheumatology and Clinical Immunology, Charité - University Medicine Berlin, Free University and Humboldt University Berlin, Berlin, Germany
Background/Purpose: Rituximab (RTX) has shown clinical efficacy but up to 40 % of RTX treated rheumatoid arthritis (RA) patients are poor responders (Ann-Rheum-Dis. 2005 Feb;64(2):246-52)…
Abstract Number: 44 • 2017 ACR/ARHP Annual Meeting
Characterization of Novel Stromal-Derived Autoantigens Recognized By RA Synovial Monoclonal Antibodies
Elisa Corsiero¹, Lucas Jagemann¹, Costantino Pitzalis² and Michele Bombardieri³, ¹Centre for Experimental Medicine & Rheumatology, William Harvey Research Institute, Queen Mary University of London, London, United Kingdom, ²Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, Barts and The London, School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom, ³Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, Queen Mary University of London, London, United Kingdom
Background/Purpose: We previously showed that up to 40% of RA synovial recombinant monoclonal antibodies (RA-rmAbs) generated from germinal center-like structure (GC-LS+) RA synovium recognize citrullinated…
Abstract Number: 676 • 2017 ACR/ARHP Annual Meeting
Immunosignature Autoantibody Profiles Provide Mechanistic Insight into Systemic Lupus Erythematosus and Differentiation from Symptomatically Overlapping Diseases
Theodore M. Tarasow¹, Robert Gerwien¹, Jonathan Melnick¹, Scott A. Melville¹ and Chaim Putterman², ¹HealthTell, Inc., San Ramon, CA, ²Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY, USA, Bronx, NY
Background/Purpose: Diagnosis and monitoring of patients with SLE usually requires careful evaluation by a rheumatologist. However, difficulties in accurately quantifing disease and treatment response can…
Abstract Number: 2335 • 2017 ACR/ARHP Annual Meeting
Antiendothelial Cell Antibodies in Juvenile Dermatomyositis: A Proteomics-Based Approach
Rie Karasawa¹, Mayumi Tamaki¹, Toshiko Sato¹, Megumi Tanaka¹, Kazuo Yudoh¹ and James Jarvis², ¹Institute of Medical Science, St. Marianna University School of Medicine, Kawasaki, Japan, ²Department of Genetics, Genomics & Bioinformatics, University at Buffalo, Buffalo, NY
Background/Purpose: Juvenile dermatomyositis (JDM) is a systemic disorder of childhood characterized by muscle inflammation and vasculopathy. The mechanisms of the blood vessel injury in JDM…
Abstract Number: 2658 • 2017 ACR/ARHP Annual Meeting
4-Hydroxy-2-Nonenal Serum Protein-Adducts and Anti-4-Hydroxy-2-Nonenal-Protein Adduct Antibodies in SLE
Biji T Kurien^1,2,3 and R. Hal Scofield⁴, ¹Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²U.S. Department of Veterans Affairs Medical Center, Oklahoma City, OK, ³College of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁴Arthritis & Clinical Immunology Program, Oklahoma Medical Research Foundation; Department of Medicine, University of Oklahoma Health Sciences Center; US Department of Veterans Affairs Medical Center, Oklahoma City, OK
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic, complex disease and autoantibodies to self-antigens are a characteristic feature of the disorder. Our group and others…
Abstract Number: 17 • 2017 Pediatric Rheumatology Symposium
Anti-endothelial cell antibodies in juvenile dermatomyositis
Rie Karasawa¹, Mayumi Tamaki¹, Toshiko Sato¹, Megumi Tanaka¹, Kazuo Yudoh² and James Jarvis³, ¹Institute of Medical Science, St. Marianna University School of Medicine, Kawasaki, Japan, ²Institute of Medical Science, St. Marianna University School of Medicine, Kanagawa, Japan, ³Pediatrics, SUNY Buffalo School of Medicine, Buffalo, NY
Background/Purpose: Juvenile dermatomyositis (JDM) is the most common form of inflammatory myopathy in children. Although classified as a myopathy, involved tissues in JDM are characterized…
Abstract Number: 1083 • 2016 ACR/ARHP Annual Meeting
Discovery and Subsequent Diagnostic Verification of Autoantibodies Against the Major Vault Protein (MVP) in Systemic Lupus Erythematosus
Petra Budde¹, Johannes Schulte-Pelkum¹, Daniel Wirtz¹, Hans-Dieter Zucht¹, Heike Göhler¹, Stefan Vordenbäumen², Peter Schulz-Knappe¹ and Matthias Schneider³, ¹Protagen AG, Dortmund, Germany, ²Rheumatology, Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany, ³Rheumatology, Heinrich-Heine-University, Duesseldorf, Germany
Background/Purpose: In systemic lupus erythematosus (SLE), early diagnosis and prognostic stratification are still great challenges. The broad characterization of the autoantibody repertoire in SLE is…
Abstract Number: 1208 • 2016 ACR/ARHP Annual Meeting
High-Throughput Screening Discovers Multiple Novel Autoantibodies in Rheumatoid Arthritis, Systemic Lupus, Systemic Sclerosis and Sjogrens Syndrome
Peter Schulz-Knappe¹, Hans-Dieter Zucht¹, Petra Budde¹, Heike Göhler¹, Daniel Wirtz¹, Johannes Schulte-Pelkum¹, Stefan Vordenbäumen², Torsten Witte³ and Prof. Dr. Matthias Schneider⁴, ¹Protagen AG, Dortmund, Germany, ²Rheumatology, Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany, ³Department of Clinical Immunology and Rheumatology, Hannover Medical School, Hannover, Germany, ⁴Department of Rheumatology & Hiller Research Unit, Heinrich-Heine University, Düsseldorf, Germany
Background/Purpose: Diagnostic biomarkers are decision-making tools in clinical lab routine and are of growing importance for clinical management of patients. In autoimmune diseases, one important…
Abstract Number: 1834 • 2016 ACR/ARHP Annual Meeting
Commensal Ro60 Autoantigen Ortholog Cross-Reactivity in Human Lupus and Gnotobiotic Models
Teri Greiling¹, Carina Dehner², Stephen Renfroe³, Xinguo Chen⁴, Kevin Hughes⁴, Silvio M. Vieira³, William Ruff³, Marco Boccitto⁴, Andrew Goodman⁵, Sandra L. Wolin⁴ and Martin Kriegel^3,6, ¹Dermatology and Immunobiology, Yale School of Medicine, New Haven, CT, ²Immunobiology, Yale School of Medicine, new haven, CT, ³Immunobiology, Yale School of Medicine, New Haven, CT, ⁴Cell Biology, Yale School of Medicine, New Haven, CT, ⁵Microbial Pathogenesis, Yale School of Medicine, New Haven, CT, ⁶Medicine/Division of Rheumatology, Yale School of Medicine, New Haven, CT
Background/Purpose: The earliest autoantibodies in lupus are directed against the autoantigen Ro60, an RNA binding protein with orthologs that we identified in a subset of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].